Know more

Lung transplantation is the only treatment for selected patients with chronic respiratory insufficiency. Graft survival rate at 5 years is 50% and mainly related to graft rejection and/or the secondary effects of immunosuppressive drugs. Lung transplantation management has improved recently due to the normothermic ex vivo lung perfusion which extends the number of suitable donor lungs and reduces primary graft dysfunction, a risk factor of allograft failure. In the V2I team, we follow four lines of research all related to lung innate immunity, with a particular focus on macrophages and dendritic cells, in the pig model and in human patients:

1) deciphering the physiopathology of ischemia-reperfusion and its link with primary graft dysfunction and subsequent rejection episodes

2) understanding and improving the donor lung preconditioning (normothermic ex vivo lung perfusion)

3) development of immunomodulatory strategies targeting macrophages and dendritic cells in the pig model

4) identification of biomarkers at the perioperative stage associated with clinical and graft outcomes.

Collaborations: L. Jouneau (VIM-Jouy), C. Bevilacqua (GABI-Jouy), J.J. Leplat (GABI-Jouy), C. Richard (BREED-Jouy), S. Brouard (CRTI-Nantes), C. Linard (IRSN), N. Bertho (BIOEPAR-Nantes), M. Dalod and T. Vu Manh (CIML-Marseille), E. Jamin (Toxalim-Toulouse), J. Selim (Rouen)